Abstract
Background and aims Sparse data exist on the possible risk of adverse pregnancy outcomes in women with familial hypercholesterolemia (FH). We investigated associations between having a FH diagnosis and adverse pregnancy outcomes, and between statin exposure in pregnancy and adverse pregnancy outcomes among women with FH.
Methods This registry-based study included 3869 pregnancies among 1869 women with FH and 68225 pregnancies among 33661 women from the general population. Data on adverse pregnancy outcomes were obtained from the Medical Birth Registry of Norway with data from 1967-2018. Data on pharmacy-dispensed statins were obtained from the Norwegian prescription database (2004-2018) in 1051 women with FH. Associations were presented as odds ratio (OR) with 95% CI from logistic regression adjusted for mother’s age, parity, and offspring’s birth year.
Results Women with FH had a higher risk of preeclampsia (OR 1.21 [1.00-1.46]), but lower risk for gestational diabetes (OR 0.58 [0.36-0.92]) and intrapartum hemorrhage during delivery (OR 0.81 [0.71-0.92]) compared to controls. No excess risk of adverse pregnancy outcome in offspring was observed for FH vs controls. Women with FH using statins in pregnancy (n=260) had a higher risk of having offspring with low (<2500 g) birth weight (OR 2.20 [1.11, 4.49]) compared to non-exposed women with FH (n=791).
Conclusions Women with FH had lower risk of gestational diabetes and intrapartum hemorrhage during delivery and non-significantly higher risk of preeclampsia compared to controls. No difference in adverse pregnancy outcomes in the offspring was observed. Statin exposure in pregnancy was associated with a higher risk of having offspring with low birth weight among women with FH, and this association warrants further investigations.
Competing Interest Statement
KS, JJC, JI, HWK, LJM, DRJ, declare no conflict of interest. MPB has received honoraria for lectures from Amgen, Sanofi, Novartis and Ultragenyx. KR has received personal consultation honoraria from Norwegian Medicina Products Agency, and payment to Oslo University Hospital from Thrombolysis in Myocardial Infarction (TIMI) Study Group and honoraria for consultation to, in addition to honoraria for lectures from Amarin, Amgen, Novartis and Sanofi. KBH has received honoraria from Sanofi and is a member of the Scientific Advisory board of FH Europe Foundation.
Funding Statement
The study is funded by Helse Sor ost RHF (Norway), award number 2018095. PI: Kjetil Retterstol.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by The Regional Committee of Medical and Health Research Ethics for South-Eastern Norway (reference 2011/1343), and by the Norwegian Data Protection Officer at Oslo University Hospital. The implementation of the study complies with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
